Comprehensive genomic profiling from
a blood sample. Fast.
Easy to interpret report informs first-line decisions and beyond
Blood Sample
2x 10 ml tubes of blood
7 days
Comprehensive genomic
profiling results in
only 7 days
Take action
Clinically relevant alterations
in 70+ cancer related genes.
For patients with advanced solid tumour cancers
-
Before 1st Line Treatment
Get ahead of the challenges of tissue testing in advanced NSCLC by utilizing Guardant360® to guide 1st line treatment decisions
-
At Progression
Get genomic information on over 70+ genes, including MSI across multiple solid tumors to help find cancer therapies and clinical trials.
PUBLISHED DATA
Prospective study of 323 NSCLC patients found Guardant360® improved alteration detection1 1. Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 2018 Oct 11. doi: 10.1001/jamaoncol.2018.4305. [Epub ahead of print.]
were unable to get complete genomic results from tissue biopsy
had targetable alterations detected by Guardant360® and tissue testing (n=82) versus tissue testing alone (n=47)
treated based on Guardant360® had a response or stable disease
Subscribe to our Newsletter
to stay up to date with information
on Liquid Biopsy and Guardant Health services
Consistently High Concordance with Tissue
for targetable alterations before 1st NSCLC therapy1 1. Aggarwal C, Thompson JC, Black TA, et al. Clinical implications od plasma-based geontyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 2018 Oct 11. doi: 10.1001/jamaoncol.2018.4305. [Epub ahead of print.]
Consistently High Concordance with Tissue
Best-in-class detection
Extensively peer reviewed and published
Published analytical and clinical validation (refs)
Over 150 peer reviewed publications, more than 50 of which include associated clinical outcomes
Tissue has limitations beyond your control
- Treatment delays
- Patient burden
- Finite resource
- Practice/staff burden
Relying solely on tissue leads to undergenotyping
~ 1 in 2 NSCLC patients are unable to get guideline-recommended genes for NSCLC2-6
2. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998-2006. 3. Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 2018 Oct 11. doi: 10.1001/jamaoncol.2018.4305. [Epub ahead of print.] 4. Thompson JC, Yee SS, Troxel AB, et al. Personalized medicine and imaging detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res. 2016;(22):5772-5782. 5. Vigneswaran J, Tan YH, Murgu SD, et al. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. 2016;7(14):18876-18886. 6. Hagemann IS, Deverakonda S, Lockwood CM, et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer. 2015;121(4):631-639
EGFR
ALK
ROSI
BRAF
MET
RET
ERBB2 (HER2)
NTRK
Everything you need
to get started
PHYSICIAN PORTAL
-
On-call support for healthcare professionals and patients -
Easy access to reports via online portal, or app